A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a metabolic checkpoint against anti-cancer immune responses.

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

When Roy Bradley was told he had cancer in his lungs and liver, his first thought was he couldn't face chemotherapy and ...

Despite past setbacks, Zymeworks' partnerships, potential milestones, and large target markets present significant upside ...

A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a ...

After issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody ...

Today, as we mark World Malaria Day, we're highlighting innovative approaches that can drive progress toward eliminating this ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Synthetic Design Lab, a next-generation antibody-drug conjugate (ADC) company advancing its novel SYNTHBODY therapeutic ...

The proposed transaction values VERAXA Biotech AG at USD 1.64 billion with expected gross cash proceeds up to USD 253 million held in trust by Voyager Acquisition Corp.